BMY Q3 Beat Supports Bridge Thesis, But Policy and Pipeline Risks Persist

What happened

Bristol Myers Squibb reported third-quarter 2026 results that beat analyst estimates, driven by continued strength in its Growth Portfolio and promising pipeline assets, sending shares up 3%. This beat corroborates management's narrative that newer brands can offset legacy declines, as the Growth Portfolio's double-digit growth absorbs pressure from generic competition on drugs like Revlimid. Critically, the results suggest that the company is meeting its 2026 guidance for gross margin (~69-70%) and Eliquis growth (+10-15%) despite IRA price resets and Medicaid supply concessions, which were key watch items. However, the step-change in Revlimid erosion (volume caps ended Jan 31, 2026) and upcoming pivotal readouts (Librexia AF/STROKE) remain unresolved risks that could undermine the bridge-year thesis. Overall, the quarter confirms the company's operational resilience, but investors should still demand full-year execution before turning fully bullish.

Implication

The Q3 beat removes a major near-term overhang by demonstrating that Eliquis volume growth and gross margin stability are achievable despite aggressive pricing policy. Investors who were waiting for confirmation before adding can now initiate or add to positions, ideally near the attractive entry of $55-60. However, the stock's move to ~$62-63 after the beat leaves limited upside to the base-case fair value of $65, and the bear case of $52 remains possible if Revlimid erosion accelerates or pipeline readouts disappoint in the coming months. Therefore, a disciplined approach is to buy on weakness rather than chase strength, and to trim if the stock approaches $70, which is above the base-case fair value. Full-year 2026 results, especially gross margin and Eliquis growth against the guided range, will be the ultimate arbiter of whether the bridge-year thesis is intact.

Thesis delta

The prior WAIT rating was predicated on needing observable proof that management could meet 2026 guidance while sustaining gross margin and Eliquis growth. The Q3 beat provides initial confirmation that this is achievable, reducing the risk of a margin-led de-rating and slightly increasing confidence in the base case. However, the thesis does not yet warrant an upgrade to BUY because Revlimid's volume-cap removal and 2H26 pipeline readouts still pose binary risks that could derail the bridge-year narrative.